These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 15883662)

  • 1. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M; Bultink IE; Dijkmans BA; Lems WF
    Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
    Omidvar B; Ghorbani A; Shahbazian H; Beladi Mousavi SS; Shariat Nabavi SJ; Alasti M
    Iran J Kidney Dis; 2011 Nov; 5(6):420-4. PubMed ID: 22057076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
    Heijckmann AC; Juttmann JR; Wolffenbuttel BH
    Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.
    Eekman DA; Vis M; Bultink IE; Derikx HJ; Dijkmans BA; Lems WF
    BMC Musculoskelet Disord; 2009 Jul; 10():86. PubMed ID: 19604377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA; Peel N; McCloskey E; Walsh JS; Eastell R
    Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to alendronate in osteoporotic women previously treated with pamidronate.
    Peretz A; Siderova V; Body JJ; Dumon JC; Rozenberg S; Fellemans C; Fuss M; Bergmann P;
    Maturitas; 2003 Feb; 44(2):111-5. PubMed ID: 12590006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous pamidronate in the treatment and prevention of osteoporosis.
    Chan SS; Nery LM; McElduff A; Wilmshurst EG; Fulcher GR; Robinson BG; Stiel JN; Gunton JE; Clifton-Bligh PB
    Intern Med J; 2004 Apr; 34(4):162-6. PubMed ID: 15086695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD; Epstein S; Sedarati F; Reginster JY
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
    Al-Bogami MM; Alkhorayef MA; Bystrom J; Akanle OA; Al-Adhoubi NK; Jawad AS; Mageed RA
    Saudi Med J; 2015 Nov; 36(11):1305-11. PubMed ID: 26593163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
    Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
    Ryan PJ; Blake GM; Davie M; Haddaway M; Gibson T; Fogelman I
    Osteoporos Int; 2000; 11(2):171-6. PubMed ID: 10793877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
    Chávez-Valencia V; Arce-Salinas CA; Espinosa-Ortega F
    J Clin Densitom; 2014; 17(4):484-9. PubMed ID: 24613450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.